Qilu Pharmaceutical has achieved a noteworthy milestone in the realm of innovative drug research and development. This year, the company has secured clinical trial approvals for five Class 1 new drugs, encompassing avant-garde areas like antibody-drug conjugates (ADCs) and triple-antibody technology. Notably, QLS5132 for injection stands as the first ADC drug targeting its class in China. QLS4131 has made strides in both oncology and autoimmune diseases. The QLS1209 tablets and QLS12010 capsules exhibit promising potential in treating solid tumors and autoimmune diseases, respectively. Furthermore, QLS1304 tablets have garnered simultaneous approvals in both China and the United States. Additionally, Qilu Pharmaceutical has obtained clinical approvals from the US Food and Drug Administration (FDA) for four innovative drugs, with multiple projects achieving global synchronized research and development.